Takeda Pharmaceutical (NYSE:TAK) is now covered by analysts at Morgan Stanley. They set an "overweight" rating on the stock.
Takeda Pharmaceutical (TSE:4502) Valuation Check As Shares Show Strength Over Recent Periods [Yahoo! Finance]
Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)
Celiac Disease Market Report 2025-2035: Drivers, Challenges, Opportunities, Industry Trends and Case Studies [Yahoo! Finance]
Blending Data and Local Knowledge To Enable Sustainable Outcomes [Yahoo! Finance]